Intraperitoneal (i.p.) injection of a mineral oil such as pristane induces a chronic inflammatory response in mice. This is characterized by a large influx of macrophages and other inflammatory cells into the peritoneal cavity for months after injection of the oil. By using the B9 cell bioassay, it was found that injection of pristane caused a marked and prolonged elevation of interleukin-6 (IL-6) levels in the peritoneal cavities of the mice. IL-6 was undetectible (e15 U/mL) in the peritoneal fluids of unprimed mice and during the first week after injecting pristane. From 4 t o 20 weeks, the concentration of IL-6 increased t o an apparent plateau with concentrations ranging from 200 t o 2,000 U/mL. Increasing the dose of pristane did not substantially increase the peritoneal levels of IL-6 established at 20 weeks after pristane treatment. At later times (by day 250). the level decreased t o 263 f 217 U/mL. However, mice that developed plasma cell tumors NTERLEUKIN-6 (IL-6)' is a multifunctional cytokine I that is elevated in inflammatory conditions in vivo.1,2
Elevation of IL-6 during bacterial or viral infection or in response to injury is thought to modulate a normal acutephase response and is a transient phenomenon that usually subsides within hours or days after infecti~n.~v~-~ However, a chronically elevated IL-6 level is a marker for disease and is probably pathogenic? A major biologic function of IL-6 involves modulation of B-lymphocyte differentiation and pr~liferation.~ Accordingly, dysregulation of IL-6 production is often associated with pathologic conditions that involve abnormal B-cell proliferation. It is strongly implicated in the pathophysiology of multiple myeloma, the most common human plasma cell tumor.IO IL-6 is an essential growth factor for myeloma cells in c~l t u r e~~-'~ and chronically elevated levels that appear to correlate with severity of the disease are found in the serum of myeloma patients.14J5 In addition, abnormal IL-6 production has been found in cells from patients with both Hodgkin's16 and nonHodgkin's lymphoma,17J8 B-cell chronic lymphocytic leukemia,19 cardiac myxoma,20 and Castleman's disease.21 Recently it has been found that human immunodeficiency virus (H1V)-infected monocytes and macrophages secrete elevated levels of IL-6 and that patients with acquired immunodeficiency syndrome (AIDS) have increased serum concentrations of this IL.22,23 This disease, which involves repeated infection by various environmental pathogens, is characterized by pronounced lymphadenopathy, hyperglobulinemia, and the eventual formation of B-cell lymphomas around day 300 showed high levels of IL-6 in the ascites fluid (650 t o 2,400 U/mL). Serum levels of IL-6 were also elevated in pristane-primed mice but were substantially lower than those found in the peritoneal cavity. Chronic administration of the nonsteroidal anti-inflammatory drug indomethacin decreased the levels of IL-6 by 75% t o 80%. Experiments performed in vitro showed that pristane-elicited macrophages secreted low levels of IL-6 constitutively and high levels of IL-6 in the presence of lipopolysaccharide. Both IL-6 and prostaglandin Ez production were inhibited by addition of indomethacin t o macrophage cultures in vitro. Treatment of mice with pristane may provide a model system for studying the inflammatory pathways that control IL-6 levels in vivo. The relevance of these results t o elucidation of the role of IL-6 in plasma cell tumorigenesis is discussed.
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in some patients.% Finally, chronic high levels of IL-6 are found in the synovial fluid and serum of patients with rheumatoid arthritis,z-z a chronic inflammatory, autoimmune disease involving abnormal B-cell activation and monoclonal gammopathy. Despite wide interest in the biology of IL-6, experimental systems to study its regulation in vivo are limited.
Our interest in IL-6 stems from its potential involvement in the pathogenesis of plasma cell tumors in mice. Plasmacytomas are induced in BALB/c mice by the intraperitoneal (i.p.) injection of mineral oils, such as pristane, that induce a chronic inflammatory response.29 This is characterized by the prolonged influx of large numbers of macrophages into the peritoneal cavity. The strict growth dependence of most plasmacytoma cell lines on IL-6 led to the hypothesis that IL-6 may be supplied by the macrophages elicited by the Despite circumstantial evidence that IL-6 is an essential factor for plasmacytomagenesis, the possibility that it is actually elevated in vivo in response to pristane has not been shown directly.
Indomethacin is a nonsteroidal anti-inflammatory drug that has been used clinically to treat chronic inflammatory conditions such as arthritis and g o~t .~~,~~ Administration of this drug in the drinking water of pristane-treated mice completely abrogates pla~macytomagenesis.3~ The biochemical mechanism whereby this occurs is not known. Because indomethacin does not inhibit the gross inflammatory condition induced by injection of pristane, it is thought to act by inhibiting specific biochemical pathways that are essential to the tumorigenic process. The results presented herein demonstrate that injection of pristane into BALB/c mice leads to highly elevated levels of i.p. IL-6 and that indomethacin inhibits this response. trol mice were treated identically except that no pristane was administered. Peritoneal lavage samples were collected by injecting and draining 8 mL of Dulbecco's phosphate-buffered saline (PBS; without Ca2+ or Mg2+). Individual lavage samples were centrifuged for 15 minutes at 2,500 rpm at 10°C. The oily pristane layers were removed and cell-free supernatants were sterilefiltered and stored frozen (-20°C) until use. Blood was obtained by retro-orbital eye bleed. Serum was stored frozen in small aliquots until assay (within 2 months). Indomethacin (20 pg/mL) was administered in the drinking water starting on day 60 to mice that received a single 1.0-mL dose of pristane as described by Potter et al." Control mice were primed with pristane at the same time.
Total PECs are the cell pellets obtained from centrifuged lavage samples. Erythrocytes were removed by a 1-minute treatment with hypotonic ACK buffer.34 Neutrophils were removed from other PECs by density gradient centrifugation as described p r e v i o u~l y .~~,~~ Briefly, total PECs (2 to 4 x lo7 cells) suspended in PBS (2 mL) were layered onto isotonic 96% lymphocyte separation medium (LSM). The macrophage fraction, which remained as a layer above the LSM, was highly viable but was not homogeneous; it also contained lymphocytes, occasional mast cells, and up to 10% contamination with residual neutrophils. Total resident peritoneal cells isolated from untreated BALB/c mice were treated with ACK but not LSM separation. Macrophages were purified further by plating cells at a concentration of 2.5 x lo6 cells/mL (0.5 mL/well) in 24-well plastic tissue culture plates in Dulbecco's modified Eagle's medium (DMEM) containing antibiotics and allowing the macrophages to adhere at 37°C for 1 to 2 hours. Nonadherent cells were removed by washing with DMEM. At least 85% of the adherent cells were macrophages and monocytes as judged by morphology. The medium was replaced with unsupplemented DMEM (0.5 mL) and the adherent cells were cultured at 37°C in a humidified atmosphere containing 5% Con. At the times indicated in the text, the culture medium was removed from each well and centrifuged. The supernatants were divided into aliquots and stored frozen until assayed for IL-6 activity. Cell numbers and viability were quantified by hemocytometry with Trypan blue. Cell differentials were analyzed from Diff-Quick-stained cytocentrifuge slides.
IL-Mependent B9 hybridoma cells36 were cultured in a serum-free medium37 supplemented with 5% heatinactivated fetal calf serum (FCS) and IL-6. The IL-6 bioassay was performed as described by other^.^^,^^ Briefly, B9 cells were washed to remove IL-6 and were then cultured in flat-bottom 96-well plates at 3,000 cells per well. Samples to be assayed for IL-6 activity were added at serial twofold dilutions. After 3 days of culture, cell proliferation was assayed by adding either 3H-thymidine (0.5 pCi) for 4 hours or by adding the colorimetric reagent MTT (0.55 mg/mL) for 2 hours.39 Thymidine incorporation was quantified by scintillation counting after harvesting the cells onto glass fiber filters. The colorimetric assay, which measures cell viability, was completed by removing the medium, dissolving the blue dye crystals with acidified isopropanol (125 pL/well), and reading the optical density at 570 nm minus the background reading at 650 nm in each well using a Molecular Devices plate reader (Menlo Park, CA). All test samples were assayed at least twice. Standard curves with recombinant murine IL-6 (mrIL-6) were run to control for inter-assay variation. The data were calculated using a fourparameter fit analysis. A unit of activity was defined as the dilution that gave half-maximal B9 cell growth in 3 days and corresponded to approximately 2 pg/mL of homogeneous mrIL-6. The results obtained with the radioactive and colorimetric assays were identical.
Because the endogenous peritoneal proteins are diluted with PBS during the lavage process, the concentrations of IL-6 and
Fractionation ofperitoneal exudate cells (PECs).
Bioassay for ZL-6. protein in the peritoneum had to be calculated by determining a dilution factor. This was accomplished by collecting both ascites (direct needle biopsy) and lavage samples from 20 different mice and analyzing the amounts of IL-6 in each. The results showed that the lavage process diluted the in vivo IL-6 by an average of 15-fold. This factor was used in all subsequent calculations.
Protein concentration in lavage samples was determined both by the Bradford method@ using reagent purchased from Bio-Rad and also by measuring the optical density at 280 nm and using an extinction coefficient of 0.66 OD units per mg/mL protein based on the value for albumin. The results obtained by the colorimetric method gave protein concentrations that were 13% lower than the spectrophotometric method.
Cell culture media, FCS, and PBS were purchased from Mediatech, Inc (Hemdon, VA) or Advanced Biotechnologies (Columbia, MD). LSM was from Boehringer Mannheim (Indianapolis, IN). Escherichia coli lipopolysaccharide (LPS) 055:B5 was from Difco Laboratories (Detroit, MI). M l T (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) and indomethacin were from Sigma (St Louis, MO).
[MethyL3H]-thymidine (6.7 Ci/mmol) was purchased from NEN/DuPont (Boston, MA). Diff-Quick stain was from Baxter Healthcare Corp (Miami, FL). Protein assay reagent was purchased from Bio-Rad (Richmond, CA). Radioimmunoassay kits for prostaglandin E2 (PGE2) were purchased from Advanced Magnetics, Inc (Cambridge, MA). mrIL-6 purified to homogeneity in the Laboratory of R. Nordan (NIH) was obtained from R. Brown of this laboratory. Pristane was from Aldrich Chemical Co (Milwaukee, WI). Polyclonal rabbit antibody to murine IL-6 was the generous gift of R. Nordan.
Materials.

RESULTS
Celkr.
After injection of pristane, the total number of cells in the peritoneal cavity increases at least 10-fold from the 1.5 to 2 x lo6 cells found in untreated mice to an average of 2.6 ? 0.2 x lo7 (mean ? SEM, n = 16) cells per mouse found 39 to 140 days after injection of the oil (see also ref 33). Cell differentials show that the cell populations consist of 50% ? 10% neutrophils, 40% ? 10% macrophages, and less than 15% lymphocytes and monocytes. A stained cytocentrifuge slide showing a typical PEC preparation prepared 133 days after injection of pristane is shown in Fig 1. Notable are the highly vacuolized macrophages that appear to have engulfed oil.
Elevation of IL-6 in vivo after pristane-treatment of mice. To quantify the levels of IL-6 in the peritoneal cavities of the mice, peritoneal lavages were taken at different times (0 to 250 days) post-pristane as described in Materials and Methods. Cell-free supernatants were analyzed for the presence of IL-6 in the B9 cell bioassay. The results shown in Fig 2 are approximate concentrations of IL-6 in the peritoneal cavities of the mice assuming that there was no compartmentalization of the protein. Specificity of the assay for IL-6 was confirmed by adding polyclonal antibody to IL-6. Bioactivity was completely inhibited in the presence of the antibody (data not shown).
As shown in Fig 2, IL-6 was first detected in lavage samples at 4 weeks after injection of 0.5 mL pristane and increased to an apparent plateau that was sustained for the 3-month period between 55 and 157 days post-pristane. The level of IL-6 detected on any experiment day during this period ranged from 200 to 2,000 U/mL. This is equivalent to approximately 0. 4 Methods). At later times, the concentration of I M appeared to recede such that by day 250, the average level was only 273 f 217 U/mL). As can be seen in the figure, a large variation between the levels obtained in differcnt mice was consistently seen on different experiment days. Nonetheless, the levels were always highly elevated compared with control mice. I M was never found in peritoneal lavages taken from untreated mice, nor was it found in lavages taken 1, 3, and 6 days after injection of pristane. Because the lowest level of IL-6 that can be detected reliably in the B9 assay is 0.25 U/mL, it can only be said at this time that the in vivo level of IL-6 in "negative" samples was less than 15 U/mL. Control experiments ruled out the possibility that an inhibitor or antagonist of IL-6 activity might be responsi- Pristane also induced a 10-to 15-fold increase in the total protein concentration in the peritoneal cavities of the mice, as shown in Fig 3. The concentration of protein increased from 3.3 f 0.2 mg/mL 24 hours after injection of the oil to 38.3 f 13.0 mg/mL on days 133 to 140. The major protein was identified as albumin, consistent with the assumption that the influx of protein derives primarily from leakage of plasma into the peritoneal space (R.L. Levine and E. Days Post-pristane For 197 creased to a much greater degree than protein in general.
By normalizing the amount of I M activity to the amount of protein found in each sample, it can be determined that the specific activity of I M in the peritoneal cavities of treated mice increased from an undetectible level (<4.5 U/mg protein) to a maximum of 31 U/mg protein found 63 to 73 days after injection of the oil. Given that 1 U of homogeneous mrIL6 is equivalent to roughly 2 pg of protein under our assay conditions, this means that there are approximately 60 pg of IL-6 for every milligram of protein.
Elevation of IM after pristane treatment of mice was confirmed by assaying I M in the serum. These data were much less reliable because of toxicity to the B9 cells at the highest concentations of serum examined (12.5%). Heat inactivation of the serum4 did not eliminate the toxicity (data not shown). Serum levels of IL-6 were much lower than lavage levels, averaging 45.8 f 13.5 U/mL (average t SEM, n = 11) at 56 days post-pristane. Nonetheless, these were higher than serum from untreated mice, in which IM activity was almost always less than 1 U/mL (n = 40).
Assay of IL-6 in the ascites of nunor-bearing mice. To gain some measure of the amount of IM required to support proliferation of tumor cells in vivo, IL6 in the ascites fluids associated with seven primary plasmacytomas was also assayed. These tumors arose roughly 300 days after injection of three 0.5-mL doses of pristane. It was found that the concentration of I L 6 in the ascites fluids ranged from 650 to 2,400 U/mL and averaged 1,240 2 582 U/mL. By comparison, five similarly treated mice that had not developed tumors by day 329 had diminished levels of IL-6 that averaged 189 U/mL. Effect of pristane dose on peritoneal IL-6 levek. A single injection of 0.5 mL pristane represents a sub-optimal dose for inducing plasmacytomas; only 22% of BALB/c mice develop tumors under these circumstances!' The incidence of plasmacytomas can be increased to roughly 40% by increasing the dose to 1 mL and to 50% to 60% by giving three injections of pristane at 2-month intervals (3 x 0.5 mL). To determine whether the dose of pristane results in increased IL6 levels in vivo, the effects of these three pristane dose regimens on the levels of IL6 obtained at day 140 were examined. The results shown in Fig 4 reveal that all three-dose regimens induced high levels of IL6 that did not differ substantially from one another. In addition, the concentrations of protein induced by 0.5 and 1 mL pristane differed by less than 20% (data not shown).
The effect of adding indomethacin (20 pg/mL) in the drinking water of pristane-primed mice is shown in Fig 5. In the presence of indomethacin, the in vivo level of IM on day 140 reached only 404 t 58 U/mL (mean f SEM, n = 11) compared with 1,637 f 327 U/mL (n = 10) achieved in control mice. Total protein levels were slightly lower in indomethacin-treated mice (27.3 f 8.4 mg/mL v 35.0 t 6.6 mg/mL in control mice), but the specific activity of IM normalized for total protein was still only 25% as much as in the absence of indomethacin (10. early as 28 days after injection of 0.5 mL pristane when indomethacin was started on the same day; in this case, the level of IM reached an average of 184 U/mL in control mice but only 34 U/mL in indomethacin-treated mice. Indomethacin caused a40% f 10% decrease in the number of total peritoneal exudate cells recovered compared with controls. For example, in the experiment shown in Fig 5,  3 .6 x lo7 cells per mouse were recovered from control mice while 2.5 x lo7 cells per mouse were collected from indomethacin-treated mice. Nonetheless, these numbers are still more than 10-fold higher than the 1. 
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cells found in mice that had not received pristane and no substantial differences were observed in the types or morphology of cells recovered from indomethacin-treated and control mice.
Compakon of IL-6 production from resident and pristaneelicited peritoneal cells. Experiments were performed to determine whether pristane-elicited cells are activated in vivo to produce IL-6. Resident peritoneal cells and pristaneelicited PECs were isolated by peritoneal lavage and fractionated as described in Materials and Methods. The adherent cells from each were cultured in unsupplemented DMEM and cell supernatants were collected from duplicate wells at 4-hours, 1-day, and 2-day timepoints. No serum was added to the cultures because it stimulates IL-6 production42 (and E.S., unpublished observations). The data shown in Fig 6 reveal that pristane-elicited adherent cells collected 2 months (57 to 76 days) after pristane treatment produced sixfold more IL-6 in the absence of exogenous stimuli than resident peritoneal cells (178 2 40 U/mL compared with 30 f 30 U/mL). The majority of IL-&producing activity occurred between 4 hours and 1 day after starting the incubation. The plateau in IL-6 production seen between 1 and 2 days correlates with the poor appearance of the cells after 2 days of culture in the absence of any growth supplements.
Pristane-elicited PECs are subjected to an extra purification step (LSM separation) to remove the large numbers of neutrophils that are almost never seen in resident populations. The possibility that the LSM step might have activated the PECs was ruled out by subjecting resident peritoneal cells to the same treatment. No increase in activity was observed (data not shown).
Effect of indomethacin on production of IL-6 in vitro.
Experiments were performed to determine whether indomethacin directly inhibits IL-6 production from pristane- elicited macrophages and to determine whether this correlates with inhibition of PGEz formation. Cells (1.1 x 106/ well) were stimulated with LPS (0.1 to 1 pg/mL) in the presence or absence of 2 pmol/L indomethacin. The levels of IL-6 and P G b in the cell supernatants were assayed after a 1 day culture (Table 1) . In three separate experiments, indomethacin inhibited IL-6 production by 54% to 64% depending on the level of stimulation of the cells. Under the same conditions, PGE2 production was completely abolished.
DISCUSSION
BALB/ cAn mice sustained high levels of i.p. IL-6 during a 5-month period after injection of pristane. Such a prolonged elevation of IL-6 in response to an exogenous agent has not been previously documented. Transient elevations in IL-6 are observed experimentally after injection of endotoxin or bacteria to and after renal transplantation: and during acute i n f e~t i o n . 5 ,~,~.~~ In resolving the acute inflammation that results from these conditions, IL-6 is restored to normal levels within hours to days. However, pristane is a paraffin oil that leads to a chronic inflammatory condition largely because it is poorly removed from the system.& Hence, the most likely explanations for the prolonged increase in IL-6 derive from the chronic peritoneal inflammation induced by the 0il.4~
The data point to three factors in this process: (1) the prolonged presence of large numbers of inflammatoly macrophages in the peritoneal cavity; (2) activation of these cells to produce IL-6 in vivo; and (3) limited removal of the IL-6 from this compartment. During the first 24 to 48 hours after injection of the oil, the predominant cells recovered from the peritoneal cavity are neutrophils. Thereafter, large numbers of macrophages also are elicited; at any time between 3 days and 5 to 6 months after the injection of pristane, the number of peritoneal macrophages is at least 10 times higher than in untreated mice. These cells were activated to produce IL-6, secreting approximately six times more in the absence of exogenous stimuli than resident macrophages isolated from untreated mice (see Fig 6) . The mechanism whereby they are activated in vivo is not known. One possibility is the phagocytosis of oil; pristane-elicited macrophages contain large vacuoles of engulfed oil, but the potential effects of this on macrophage activity have not Localization and duration of the IL-6 response.
For ELEVATION OF IL-6 IN CHRONIC INFLAMMATION   199 been determined. Alternatively, the cells may be stimulated in vivo by other cytokines that constitute part of the inflammatory response to This possibility is supported by recent findings that interferon-y is also elevated in the peritoneal fluids of pristane-treated m i~e . 4~ An oxidant stress induced by the large number of neutrophils in the peritoneal cavity could also activate IL-6 production by the macrophage A different physiologic stimulus may derive from LPS30; it was reported51 that peritoneal levels of endotoxin increased from 0.1 ng/mL to 1 ng/mL over 2 to 23 months after injection of mineral oil or pristane. The increase was ascribed to leakage of LPS from the gut during the chronic peritonitis that results from inability of the mice to remove the oil. In our hands, concentrations of E coli LPS (strain 055:B5) below 10 ng/mL did not stimulate either pristane-elicited or resident macrophages in culture during a 1-day incubation (E.S. and G.K.A., manuscript in preparation). However, we do not know how chronic exposure to LPS from endogenous gut bacteria would affect macrophage activity.
The potential contribution of other cell types in the peritoneal cavity cannot be ruled out but is not expected to be large. Lymphocytes comprise only a minor portion of free peritoneal exudate cells during the first 3 months after injection of pri~tane.3~ Although both T and B cells have the capacity to secrete IL-6 in vitro, they produce much less than activated macrophage^.^,^^ Serum levels of IL-6 also increased after injection of pristane. However, they were significantly lower than those found in the peritoneal cavity. Similar findings have been made in other ~ystems.~,~5,5~ The reasons for the large differences in systemic versus tissue levels are not known but probably derive both from localized production of the IL and to a longer half-life in the restricted tissue compartments. The general accumulation of proteins in the peritoneal cavity beginning as early as 3 days after injection of the oil combined with histologic data54 support the view that IL-6 may be retained in the peritoneal cavity because the efferent lymphatics are partially blocked. In contrast, IL-6 is rapidly cleared from the blood after acute infectior~,~,~,~ thus lowering the levels that can be achieved in the circulation.
Indomethacin lowered the observed IL-6 levels but did not prevent the overall inflammatory response. This is evident from the high numbers of inflammatory cells and proteins in the peritoneal cavity and from the continued presence of oil granuloma tissue in indomethacin-treated mice.33 The finding that indomethacin also inhibited IL-6 production from pristane-elicited macrophages in vitro indicates that a direct effect on these IL-&producing cells may account for at least some of the inhibitory activity in vivo. In fact, a 50% to 60% inhibition of macrophage activity coupled with a 40% diminution in macrophage number in the peritoneal cavity can account for the 75% to 80% inhibition in IL-6 levels in vivo. Further experiments will be required to determine whether these were the only mechanisms responsible for the IL-4-reducing action of the drug.
The most potent biochemical action of indomethacin is
Inhibition by indomethacin.
the inhibition of prostaglandin synthesis. Experiments in vitro indicated that IL-6 production by LPS-stimulated mouse peritoneal macrophages may be partly linked to prostaglandin production (Table 1) ; the drug abolished PGE2 secretion but only partially inhibited IL-6 production.
The mechanism for the effect on IL-6 is not clear. Indomethacin can inhibit other biochemical pathways,55 but at the concentration of drug used in these in vitro experiments (2 p,mol/L) it would only be expected to inhibit the cyclooxygenase This suggests that arachidonate metabolites can upregulate IL-6 secretion but that production of the cytokine can occur even in their absence. Elucidation of the interrelationship between these two pathways awaits further investigation.
The peritoneal levels of IL-6 that develop in response to pristane (-0.4 to 4 ng/mL) are expected to be sufficient to support most of the known actions of the cytokine (based on the data available from in vitro experiments). These would include modulation of B-cell pr0liferation,5~ differentiation and Ig secreactivation of T lymphocyte^,^^ and support of the proliferation of hybridomas,42,60 plasmacytoma^,^^ and multiple myeloma cells.' Of critical importance to studies on pristane-induced plasmacytomagenesis in BALB/c mice is the hypothesis that IL-6 is a causative factor in the tumorigenic process. Several lines of evidence presented both here and elsewhere support this possibility: (1) Primary plasmacytomas are dependent on addition of IL-6 or a cellular substratum that can supply IL-6 for their growth in tissue culture.3°,61,62 (2) Transfection of plasmacytoma cells with an activated IL-6 gene leads to autonomous growth in syngeneic mice and to increased malignancy.63@ This occurs despite the fact that i.p. transplantation of early generation plasmacytomas usually requires that the recipient mice first be primed with an injection of pristane in order for the tumor cells to grow in vivo.65 (3) Pristane induces highly elevated levels of i.p. IL-6 in BALB/c mice (this report) and pristane-elicited macrophages produce IL-6 in vitro without addition of exogenous stimuli30 (and this report). (4) Indomethacin inhibits plasmacytomagenesis33 and inhibits elevation of IL-6 in pristane-treated mice. It should be emphasized that the data are not sufficient to conclude whether this is the mechanism whereby the drug inhibits plasmacytomagenesis. For example, we have yet to determine how much IL-6 is required for primary plasmacytomas to develop in vivo and hence whether the levels achieved in indomethacin-treated mice are too low for this to occur.
IL-6 could promote plasmacytomagenesis by several mechanisms. Foremost is the likelihood that it supports proliferation and consequent outgrowth of abnormal plasma cells; ie, cells that have already sustained the chromosomal translocations that are ubiquitous in pristane-induced plasmacytomas.@ Consistent with this view was the observation that the levels of IL-6 found in the ascites fluids associated with primary plasmacytomas ranged from 650 to 2,400 U/mL in the B9 hybridoma assay. Given that IL-6-dependent hybridomas are approximately 100 times more sensitive to IL-6 than plasmacytoma^,^^,^^ this is equivalent
Consequences of elevated IL-6.
For personal use only. on April 2, 2017. by guest www.bloodjournal.org From 200 SHACTER, ARZADON, AND WILLIAMS to 6.5 to 24 (average 12.4 2 6.8) plasmacytoma U/mL of IL-6. As a unit of activity is defined as the amount of IL-6 required to support cell growth at 50% of maximum, these levels would certainly be expected to support plasmacytoma proliferation in vivo. In contrast, much lower levels of IL-6 were present in mice that had not developed tumors by day 300. This finding supports the concept that tumors only arise in mice that for some reason sustain a critical level of IL-6. The large variation in IL-6 levels in different individual mice may further reflect the fact that only a fraction of these mice will go on to develop p1asmacytomas:l It may be important to note that the biochemical mechanism through which IL-6 supports plasmacytoma growth is only partially understood and may derive both from stimulation of cell cycling and by inhibition of apoptosis (R. Nordan, personal communication), as has been suggested for other tumorpromoting agents.68 The nonmalignant plasmacytosis observed in IL-6 transgenic in Castleman's disease,z1 and in cardiac myxomaz0 suggests that elevated IL-6 is not sufficient to cause plasmacytomas in the absence of mutagenic events occurring in susceptible B cells?O In this regard, our finding that increasing the dose of pristane did not increase the levels of IL-6 detected at day 140 supports the notion that repeated injections of pristane promote higher incidences of plasmacytomas by a separate, possibly mutagenic mechanism. Finally, a hypothesis in which IL-6 acts late in the tumorigenic process (eg, in tumor outgrowth) would help explain why indomethacin effectively inhibits plasmacytomagenesis even when it is added as late as 60 to 160 days after injection of pristane.33
In conclusion, the murine plasmacytoma system may provide an animal model for studying the mechanisms that control IL-6 production during chronic inflammation and for elucidating the role of IL-6 in B-cell neoplasia. A clear cause-and-effect relationship is achieved after injection of a pure inflammatory stimulus, pristane, into the peritoneal cavities of the mice and the development of elevated levels of IL-6 invivo. The fact that BAL.B/c mice tolerate pristane well during the first several months after injection of the oil allows for a relatively long experimental observation period. The availability of innumerable inbred mouse strains for which there are extensive genetic data should facilitate identification of genes that control IL-6 production during the immune response. Elucidation of the mechanism of action of indomethacin in this system may aid in the identification or design of other drugs that might be effective in treating human disease in which IL-6 is implicated.
